ACE-031: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 10 sources cited
Overview
ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) fused to a human IgG1 Fc domain. It functions as a soluble decoy receptor or 'myostatin trap,' intercepting myostatin and other TGF-β superfamily ligands before they can bind to muscle cells and inhibit growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy, it produced remarkable muscle-building effects in early clinical trials before both of its Duchenne trials were terminated over nosebleeds and dilated skin vessels.
Mechanism of Action
ACE-031 circulates in the bloodstream as a decoy receptor, binding with high affinity to multiple TGF-β superfamily ligands that normally suppress muscle growth. Its primary targets include myostatin (GDF-8), activin A, activin B, and GDF-11 — all of which signal through the endogenous ActRIIB receptor to activate Smad2/3 phosphorylation and suppress muscle protein synthesis. By sequestering these negative regulators, ACE-031 effectively removes the biological brake on skeletal muscle hypertrophy. When myostatin and activins are trapped, the Smad2/3 inhibitory pathway is deactivated, allowing the mTOR and Akt/PKB pathways to proceed unchecked. This results in increased muscle protein synthesis, enhanced satellite cell activation and fusion, and muscle fiber hypertrophy — predominantly in fast-twitch (type II) fibers. The IgG1 Fc domain extends the compound's half-life through FcRn-mediated recycling, enabling bi-weekly dosing. Notably, ACE-031's broad ligand capture means it affects more than just myostatin. The trapping of activin A may contribute to both its potent muscle effects and some of its side effects, as activins play roles in vascular homeostasis. This broad activity profile distinguishes it from selective myostatin antibodies and explains both its dramatic efficacy and its clinical challenges.
ACE-031 Benefits: What the Research Shows
- A Phase I trial in 48 healthy postmenopausal women found that a single 3 mg/kg dose increased total body lean mass by 3.3% at day 29, measured by DXA.
- At the 3 mg/kg dose, thigh muscle volume increased by 5.1% as measured by MRI, confirming true muscle hypertrophy rather than water retention.
- Drug exposure rose in proportion to dose, but the gain in lean mass reached statistical significance only in the 3 mg/kg group.
- Preclinical studies in mdx mice (the standard Duchenne muscular dystrophy model) showed a 33% increase in lean muscle mass over 12 weeks, with higher force production in isolated muscle.
- Bone mineral density was not shown to increase: the Duchenne trial found only a trend toward higher density, and the Phase I trial saw changes in bone metabolism markers rather than density itself.
- The single 3 mg/kg dose in healthy volunteers was generally well tolerated, with injection site redness the reported adverse event. The nosebleeds and telangiectasias appeared later, with repeated dosing at 0.5 and 1 mg/kg in boys with Duchenne muscular dystrophy, and stopped that trial.
- Acceleron's related compound ACE-083 (a locally-acting version) increased muscle volume in trials in facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease but was discontinued when it missed its functional endpoints, while luspatercept (ACE-536), a modified version of the same receptor trap, was successfully developed for anemia.
ACE-031 Dosage
- Phase I trial doses ranged from 0.02 to 3 mg/kg, given as a single subcutaneous dose. Only the 3 mg/kg dose produced a significant gain in muscle.
- Preclinical doses in mouse models: a soluble ActRIIB-Fc at 10 mg/kg for 12 weeks produced a 33% increase in lean muscle mass in mdx mice.
- No established off-label human protocol exists. Researchers typically extrapolate from the 1 mg/kg clinical dose, administered every 14 days.
- The compound has a long half-life due to its Fc domain (mean 10 to 15 days in the Phase I study), supporting every-other-week dosing.
- Development stopped after both Phase II trials in Duchenne muscular dystrophy were terminated on preliminary safety data, over nosebleeds and telangiectasias at 0.5 and 1 mg/kg.
- If used in research settings, baseline and periodic monitoring of platelet counts, coagulation parameters, and vascular markers is recommended.
- Subcutaneous injection is the standard route. Reconstitute lyophilized powder with sterile water per vial instructions.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
ACE-031 Side Effects & Safety
Known Side Effects
- Epistaxis (nosebleeds) — reported with repeated dosing at 0.5 and 1 mg/kg in the Duchenne trial, related to activin A's role in vascular integrity. This was the main reason that trial was stopped.
- Telangiectasias — small dilated blood vessels near the skin surface, observed with repeated dosing at 0.5 and 1 mg/kg in the Duchenne trial.
- Gum bleeding — minor mucosal bleeding events reported alongside other vascular effects.
- Potential impact on reproductive hormones — activin A and B play important roles in the hypothalamic-pituitary-gonadal axis. Trapping these ligands could theoretically affect FSH levels and fertility.
- Muscle soreness/tightness — anecdotally reported, likely related to rapid muscle growth exceeding the adaptation rate of surrounding connective tissue.
- Long-term safety is unknown — clinical development was halted early, and no long-term human exposure data exists.
Safety Profile
ACE-031's safety profile is incompletely characterized due to early termination of clinical development. The primary concern is its broad ligand-trapping activity — by capturing not only myostatin but also activins and other TGF-β ligands, it affects multiple physiological systems beyond muscle. The vascular events in the Duchenne trial at 0.5 and 1 mg/kg (epistaxis, telangiectasias) are attributed to activin A's role in maintaining vascular integrity and angiogenesis. Contraindications would include any bleeding disorder, use of anticoagulant therapy, and active vascular disease. Given activin's role in reproductive biology, it should be considered contraindicated in women of childbearing potential without adequate contraception. There is no reproductive toxicity data available. The compound's effects on the heart, liver, and other organs with ActRIIB expression are not fully characterized. Anyone considering research use should understand this is an experimental compound with incomplete safety data and proceed with appropriate caution and medical oversight.
What to Expect
Week 1–2: After the first injection, initial changes are occurring at the molecular level — Smad2/3 signaling is being suppressed and satellite cells are activating. No visible changes yet, but some users report mild muscle fullness. Weeks 3–4: Measurable increases in lean mass begin to appear. Clinical trial data showed up to 3.3% lean mass increase within 29 days of a single dose. Muscles may feel fuller and slightly pumped. Weeks 5–8: With continued bi-weekly dosing, muscle hypertrophy becomes visually noticeable. Strength gains typically accompany the size increases. No human trial of repeated dosing has shown this: the Duchenne trial found only trends in lean and fat mass before it was stopped. Weeks 9–12: Continued gains, though the rate may begin to plateau. Monitor for any vascular side effects. Long-term data beyond 12 weeks is extremely limited in humans.
Common Stacks
IGF-1 LR3
IGF-1 LR3 provides direct anabolic signaling through the IGF-1 receptor, complementing ACE-031's removal of growth inhibitory signals. Together they create a push-pull effect on muscle protein synthesis.
Ipamorelin
Ipamorelin stimulates endogenous GH release, providing systemic anabolic support that complements ACE-031's targeted myostatin inhibition for comprehensive muscle-building.
Storage & Handling
Store lyophilized powder at -4°F to 36°F (-20°C to 2°C). Protect from light. After reconstitution with sterile water or bacteriostatic water, refrigerate at 36–46°F (2–8°C) and use within 14 days. Do not freeze reconstituted solution. Due to its protein nature, avoid vigorous shaking — gently swirl to dissolve. Shelf life of unreconstituted powder is approximately 24 months when stored properly.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013.
- Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017.
- Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy (NCT01099761). ClinicalTrials.gov. 2022.
- Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy (NCT01239758). ClinicalTrials.gov. 2013.
- Pistilli EE, Bogdanovich S, Goncalves MD, et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol. 2011.
- Cadena SM, Bogdanovich S, Khurana TS, et al. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PLoS One. 2026.
- Statland JM, Campbell C, Desai U, et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022.
- Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (NCT02927080). ClinicalTrials.gov. 2022.
- REBLOZYL (luspatercept-aamt) for injection: full prescribing information. Celgene Corporation, via DailyMed. 2026.
- The Prohibited List 2026, section S4.3 Agents preventing activin receptor IIB activation. World Anti-Doping Agency. 2026.
Related Peptides
Track ACE-031 in Your Protocol
Log your ACE-031 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free